Market Intelligence, Clinical Progress, and High-Purity Reagents for Congenital Dyserythropoietic Anemia and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDAN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDAN1 Recombinant Protein (WT) / CDAN1 (R1042W) Mutant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified, Theoretical MW confirmed. |
View CDAN1 Products |
| Gene Delivery | CDAN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View CDAN1 Products |
| Benchmark Ab | Anti-CDAN1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ELISA assays. |
View CDAN1 Products |
| Validator | CDAN1 siRNA Set For target knockdown and functional specificity verification in cellular assays. |
View CDAN1 Products |
| Related Target A | ASF1B Direct binding partner of CDAN1; crucial for histone chaperone complex and chromatin assembly assays. |
View ASF1B Products |
| Related Target B | SEC23B Associated with Congenital Dyserythropoietic Anemia Type II; essential for differential screening. |
View SEC23B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting CDAN1-ASF1B Interaction | High-purity human CDAN1 and ASF1B co-expressed or individually purified with strict sequence verification. |
| Mutant Screen (CDA I Disease Mimicry) | Custom R1042W mutant recombinant proteins produced with native glycosylation and folding in HEK293. |
| Lack of Controls | Clinical-grade sequence benchmark antibodies and validated positive controls included. |
| False Positives in Knockdown | Sequence-verified siRNA pools included for target-specific knockdown validation. |
Live CDAN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CDAN1 (Codanin-1) is transitioning from genetic disease mapping to active drug discovery. Historically known as the causative gene for Congenital Dyserythropoietic Anemia Type I (CDA I), CDAN1 is emerging as a critical node in chromatin assembly and DNA replication regulation. The next wave of R&D focuses on modulating the CDAN1-ASF1B interaction, offering therapeutic avenues not only for rare hematological disorders but also for hyper-proliferative oncology indications where chromatin assembly pathways are dysregulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / CRISPR | Academic Medical Centers, CRISPR Therapeutics | Congenital Dyserythropoietic Anemia Type I (CDA I) | Lentivirus for stable cell line rescue assays (Need sequence-verified ORF) |
| Small Molecule Modulators | Oncology-focused Biotechs | Solid Tumors, Hematological Malignancies | In vitro binding assays (Need high-purity CDAN1-ASF1B protein complexes) |
| RNA Therapeutics (siRNA) | RNAi Developers | Prostate Cancer, Stem Cell Regulation | Target knockdown validation (Need validated siRNA sets) |